Insider Selling: uniQure (NASDAQ:QURE) Insider Sells 1,350 Shares of Stock

uniQure (NASDAQ:QURE) insider Walid Abi-Saab sold 1,350 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $10.29, for a total value of $13,891.50. Following the completion of the sale, the insider now owns 151,903 shares in the company, valued at $1,563,081.87. This represents a 0.88 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link.

uniQure Trading Up 6.7 %

NASDAQ QURE opened at $12.09 on Thursday. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The company has a current ratio of 6.51, a quick ratio of 6.51 and a debt-to-equity ratio of 0.92. The company has a market capitalization of $589.30 million, a PE ratio of -2.44 and a beta of 0.38. The firm’s fifty day simple moving average is $14.69 and its 200-day simple moving average is $9.91.

Institutional Investors Weigh In On uniQure

Hedge funds have recently bought and sold shares of the company. Atria Investments Inc bought a new position in uniQure during the third quarter worth about $53,000. Privium Fund Management B.V. increased its holdings in shares of uniQure by 16.3% during the third quarter. Privium Fund Management B.V. now owns 744,916 shares of the biotechnology company’s stock worth $3,672,000 after buying an additional 104,500 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of uniQure in the third quarter valued at approximately $69,000. Charles Schwab Investment Management Inc. increased its holdings in shares of uniQure by 6.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 277,275 shares of the biotechnology company’s stock valued at $1,367,000 after purchasing an additional 16,464 shares in the last quarter. Finally, FMR LLC increased its holdings in shares of uniQure by 8,056.6% in the third quarter. FMR LLC now owns 350,572 shares of the biotechnology company’s stock valued at $1,728,000 after purchasing an additional 346,274 shares in the last quarter. 78.83% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on QURE. Stifel Nicolaus upped their target price on uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a research report on Monday, December 16th. Leerink Partners upped their target price on uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research report on Wednesday, December 11th. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Cantor Fitzgerald upped their price objective on uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Mizuho increased their target price on uniQure from $7.00 to $20.00 and gave the stock a “neutral” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

About uniQure

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.